Characterization of Microglia Transcriptional Profile in Fmr1 Knockout Mice Model

Microglia are excessively activated in Fragile X models. The team will investigate the mechanisms and attempt to correct this using drugs.

Read More »

The Role of Astrocyte BMP Signaling in Fragile X Syndrome

Researchers found a pathway in astrocytes that is overactive in Fragile X syndrome, and they hope to bring this pathway back to normal with a drug.

Read More »
Drs. Oostra, Warren, and Nelson discovered the Fragile X gene and its FRAXA mutation in 1991.

Memorial Tribute to Dr. Stephen T. Warren

Dr. Stephen T. Warren, who discovered the Fragile X gene (FRAXA) in 1991, passed away June 6, 2021. Donations in his honor support FRAXA Research.

Read More »

Meet Tyler!

Meet #FriendofFRAXA Tyler! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

Identifying Cellular and Molecular Signatures in Human Neurons That Distinguish Fragile X Syndrome Patients with Divergent EEG Profiles

Just as Fragile X affects individuals differently, medications do as well. This project aims to bring personalized medicine to Fragile X syndrome.

Read More »

Drug Tolerance in MGluR5 Clinical Trials – Dr Patrick McCamphill 1:1 with FRAXA

We have long suspected that the clinical trials of mGluR5 blockers from Novartis and Roche failed because the drug triggered tolerance, losing effect over time. With a $90,000 grant from FRAXA, Dr. Patrick McCamphill, a Postdoctoral Fellow in the MIT lab of Dr. Mark Bear, is investigating. He does indeed find tolerance, and now he is looking for ways to overcome it.

Read More »

We Started Out Small, Now Look…

Join FRAXA in lighting up the world on July 22 for World Fragile X Day—together, we shine teal for Fragile X awareness!

Read More »

NPR Feature – A Fragile X Treatment May Be On The Horizon

NPR’s Jon Hamilton looks back on a decade of Fragile X progress and the Tranfaglia family’s quest for a cure. Hear their story on NPR Short Wave.

Read More »

Pharmacotherapeutic Effects of Cannabidiol (CBD) in Fragile X syndrome (FXS) and Autism Spectrum disorder (ASD)

This study tested CBD (cannabidiol) treatment in male and female Fragile X mice to learn how and why it works and whether gender affects responses to CDB treatment.

Read More »

NPR Short Wave, “A Fragile X Treatment May Be On The Horizon”

Katie Clapp and Michael Tranfaglia’s son was born with a genetic disorder that affects brain development. It makes it hard to learn language and basic daily tasks and often is accompanied by a host of other disorders. To help find a cure, they started a foundation and raised research money. After se…

Read More »

Holly Roos Joins the FRAXA Team!

We’re thrilled to welcome Holly Roos, longtime Fragile X advocate, as FRAXA’s new Community Services Director!

Read More »

Brain & Life, “A Mom Leads Efforts to Cure Fragile X Syndrome for Her Son and Others”

We haven’t found a cure yet, but we’ve moved closer to understanding fragile X syndrome and identifying treatment targets. We hope this will help our son and other families dealing with this life-changing condition.

Read More »

Cellular-Specific Therapeutic Targeting of Inhibitory Circuits in Fragile X Syndrome

The team studied how inhibitory brain circuits malfunction in Fragile X and tested ways to restore balance by targeting mGluR and endocannabinoid signaling.

Read More »

FRAXA Supports Increased Funding for NICHD

FRAXA has joined the Friends of NICHD coalition, urging increased government funding for research into Fragile X and related conditions.

Read More »
Elizabeth MCullough and Achim Klug

Auditory Dysfunction in Fragile X Syndrome in a Mouse Model of Fragile X

FRAXA-funded studies found Fragile X mice show altered auditory circuit function with delayed startle timing and reduced prepulse inhibition, mirroring human sound sensitivity.

Read More »

Clinical Trials and Cyclic AMP in Fragile X Syndrome: A Life Journey

In November 2020, a phase II clinical trial reported extremely successful results. This clinical trial of a PDE4D inhibitor from Tetra Pharmaceuticals was conducted by Dr. Elizabeth Berry-Kravis at Rush University Medical Center and funded by FRAXA Research Foundation. In this Simons Foundation lecture, Elizabeth Berry-Kravis traces 30 years of Fragile X research, from identifying its cause, through finding dozens of treatment targets, through a series of disappointing clinical trials.

Read More »
Educating Young Children with Fragile X

Educating Young Children with Fragile X Syndrome

We share strategies, tips, techniques, and stories to help teachers and therapists who are working with young children who have Fragile X syndrome.

Read More »

The Why and How of FRAXA’s Work to Find a Cure for Fragile X

Thank you Talk Fragile X for having FRAXA’s cofounder Katie Clapp as a guest on your podcast! It was a pleasure to share why FRAXA got started and our motivation for finding effective treatments and ultimately a cure for Fragile X syndrome.

Read More »
FRAXA Grant Applications

Fragile X Research Funding of $1 Million Offered for 2021

FRAXA plans to fund $1 million for a generous number of Fragile X research grants and fellowships in 2021. Our mission is to find specific treatments and ultimately a cure for Fragile X syndrome. We aim to bring practical treatment into current medical practice as quickly as possible; we prioritize projects that have a clear practical application and the results of which will be shared in a timely fashion.

Read More »

Integrating Human and Mouse Studies in Fragile X Syndrome – an NIH Center Approach

Presentations by Craig Erickson, Ernest Pedapati, Devin Binder, and Kimberly Huber about their research on Fragile X as part of their NIH Center of Excellence.

Read More »

Developing Arbaclofen for Fragile X – Dr. Mark Bear 1:1 with FRAXA

Seven years ago, arbaclofen (STX209) was pulled from development, disappointing families around the US. Now MIT professor and FRAXA Investigator Dr. Mark Bear has founded Allos Pharma to bring it back. Dr. Bear sat down with FRAXA co-founder Katie Clapp to share the story and next steps.

Read More »

Towards Understanding the Role of FMRP in Human Brain Development Using Brain Organoids

Dr. Zhexing Wen and Dr. Peng Jin of the newly funded Fragile X Center of Excellence at Emory University School of Medicine join us in this seminar to present about Understanding the Role of FMRP in Human Brain Development Using Brain Organoids.

Read More »

Interrogate the Functions of FMRP in Brain Development Using Stem Cells

Dr. Xinyu Zhao of the Waisman Center and Department of Neuroscience at University of Wisconsin-Madison joins us in this seminar to present Interrogate the Functions of FMRP in Brain Development Using Stem Cells.

Read More »

Sincere Gratitude for a Successful #GivingTuesday 2020

From the bottom of our hearts—thank you! With 150+ donors, FRAXA raised $70,047 on #GivingTuesday. Your support brings hope to Fragile X families.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)